Risk of adverse pregnancy outcomes in women treated for malaria with dihydroartemisinin-piperaquine or quinine in the first trimester of pregnancy in Indonesia: a retrospective data analysis

Ítems similars

• Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy
  per: Poespoprodjo, JR, et al.
  Publicat: (2014)
• Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
  per: Poespoprodjo, J, et al.
  Publicat: (2015)
• Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy
  per: Chotsiri, P, et al.
  Publicat: (2021)
• Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin–piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial
  per: Ahmed, R, et al.
  Publicat: (2019)
• Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine
  per: Byakika-Kibwika, P, et al.
  Publicat: (2019)